Eli Lil­ly said Wednes­day that the US gov­ern­ment has re-upped its sup­ply of the Covid-19 treat­ment bebtelovimab, which is the last mon­o­clon­al an­ti­body or mAb treat­ment left to at­tack this lat­est strain of Omi­cron.

The US will pay $275 mil­lion for 150,000 dos­es of bebtelovimab, which comes out to about $1,833 per dose. Back in Feb­ru­ary, the US bought 600,000 dos­es for $1.08 bil­lion, or about $1,800 per dose.

Of that ini­tial tranche of 600,000 dos­es of bebtelovimab, au­tho­rized for the treat­ment of mild-to-mod­er­ate Covid-19 in those ages 12 and up, more than 490,000 have al­ready been or­dered by states, and more than 200,000 dos­es have al­ready been ad­min­is­tered, ac­cord­ing to the Of­fice of the As­sis­tant Sec­re­tary for Pre­pared­ness and Re­sponse.

De­liv­ery of dos­es will be­gin im­me­di­ate­ly and com­plete no lat­er than Aug. 5, Lil­ly said, not­ing an op­tion for an ad­di­tion­al 350,000 dos­es may be made avail­able no lat­er than Sept. 14.

While bebtelovimab is the last mAb Covid-19 treat­ment stand­ing, the FDA this week al­so ex­tend­ed the shelf life on Re­gen­eron’s mAb treat­ment, which doesn’t work against this cur­rent Omi­cron strain, and for As­traZeneca’s Evusheld, which can be used pro­phy­lac­ti­cal­ly and does work against this lat­est sub­vari­ant.

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both the accelerated and full approval’s requirements with just a single randomized controlled trial.

While Congress recently passed legislation that will allow FDA to require confirmatory trials to be recruiting and ongoing prior to granting an accelerated approval, the agency is now making clear that the initial trial used to win the AA, if designed appropriately, can also serve as the trial for converting the accelerated approval into a full approval.

Digital therapeutics company Better Therapeutics announced on Thursday that it’s cutting 35% of its staff as it awaits FDA clearance for its first product.

The company, which launched eight years ago, is one of a growing group of companies seeking a digital alternative to traditional medicine. The space saw a record $7.5 billion in investments in 2021, according to Chris Dokomajilar at DealForma, with uses spanning ADHD, PTSD and other indications. However, private insurers have been slow to hop on board.